UBS Cuts Cencora (COR) Price Target to $400
UBS has maintained its Buy rating on Cencora, Inc. while lowering its price target to $400, a 17.25% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
UBS cut its price target on Cencora, Inc. ($COR) to $400 from $430 on October 16, 2026, and rates the stock "Buy".
COR
Cencora, Inc.
Key Points
- On October 16, 2026, UBS reiterated its Buy rating on Cencora, Inc. with a new price target of $400, reduced from $430.
- UBS's $400 price target implies 17.25% upside from Cencora, Inc.'s ($COR) current $341.14 share price.
- Cencora's stock recently traded around $341.14, which is 14.7% below UBS's target price.
- The company is expected to report its next earnings on November 4, 2026.
Get $COR trade alerts by text
We text you when insiders, Congress or big funds trade $COR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Cencora, Inc. alert may contain errors. Disclosures
UBS has reiterated its Buy rating on Cencora, Inc. (NYSE: COR) on October 16, 2026, while lowering its price target to $400 from $430. The stock recently traded at $341.14, which is about 14.7% below the new target price.
UBS vs. the S&P 500
Hypothetical returns from UBS's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Cencora, Inc.
Several other institutional investors have adjusted their positions in Cencora recently. Blackrock Inc. reduced its holdings by 1,729,043 shares, bringing its total to 18,213,783 shares valued at approximately $6.21 billion. Vanguard Capital Management LLC added 65,263 shares, ending with 12,378,943 shares worth about $4.22 billion. Vanguard Portfolio Management LLC increased its stake by 21,099 shares, totaling 9,611,756 shares valued at around $3.28 billion. State Street Corporation grew its position by 83,632 shares, for a total of 9,273,983 shares valued at about $3.16 billion. T. Rowe Price Investment Management, Inc. also saw an increase, adding 1,116,609 shares to reach 7,410,910 shares worth approximately $2.53 billion.
Cencora, Inc. Stock Down 0.1%
Cencora's stock is currently trading at $341.14, which is significantly below the updated price target of $400 set by UBS. This position places the stock well below the target, indicating potential concerns among analysts regarding future performance.
$COR price target
Cencora, Inc. daily closes and this analyst's $400 target. Not advice.
Recent Earnings
Cencora reported trailing twelve-month revenue of approximately $332.77 billion and an EPS of $13.46. The company has shown a year-over-year revenue growth of 5.1%. The next earnings report is expected on November 4, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 target cuts vs 0 raises.
-
EPS & revenue
EPS missed estimates by 2.3%. Revenue missed estimates by 4.3%.
-
Profit surprise
EBITDA beat by 9 percent. Operating income met by 2 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
4 target cuts.
-
Earnings quality
Gross margin up 0.8 points. Positive free cash flow.
Earnings Call Summary
The company delivered a strong first quarter with 12 percent operating income growth and 9 percent earnings per share growth, driven by continued strength in specialty pharmaceuticals, particularly GLP-1 products which grew 11 percent. Management highlighted that US healthcare solutions performed at the high end of long-term guidance even excluding recent acquisitions like RCA and the newly closed OneOncology deal. The completion of the OneOncology acquisition marks a major strategic expansion of Cencora's managed service organization platform, which management views as a natural extension of its specialty pharmaceutical leadership.
Guidance Cencora raised full year revenue growth guidance to 7 to 9 percent from 5 to 7 percent, and operating income growth to 11.5 to 13.5 percent from 8 to 10 percent. The company closed its OneOncology acquisition and expects the MSO platform to drive meaningful operating income expansion this year and beyond.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Cencora, Inc.
Recent insider transactions included several sales. Elizabeth S. Campbell, an officer, sold 11,300 shares at an average price of $324.12 on August 24, 2026, totaling about $3.66 million. Lazarus Krikorian, also an officer, sold 985 shares at $325.97 on September 1, 2026, worth about $321,080. Additionally, Lon R. Greenberg, a director, sold 1,280 shares at $321.30 on September 16, 2026, totaling around $411,264. Another sale from Lazarus Krikorian involved 986 shares at $303.18 on October 1, 2026, amounting to about $298,935.
Analysts Set New Price Targets
On October 16, 2026, UBS maintained its Buy rating on Cencora, Inc. with a new target of $400, down from $430. Prior to this, Wells Fargo had an Overweight rating with a target of $395, and RBC Capital initiated coverage with a Sector Perform rating and a target of $330. The consensus among analysts suggests a cautious outlook, with the average target price reflecting a mix of sentiments.
About Cencora, Inc.
Cencora, Inc. is involved in sourcing and distributing pharmaceutical products both in the U.S. and internationally. The company operates in the healthcare sector, primarily focusing on medical distribution. Its operations are critical for maintaining supply chains for essential medications.
Bottom Line
Investors will be watching closely as Cencora prepares for its next earnings report on November 4, 2026. The recent adjustments in price targets from analysts highlight the need to monitor market responses to the company's performance amid evolving industry conditions.
Related Filing Alerts
Source: UBS's rating change on $COR (Oct 16, 2026). Written by software, not financial advice. How we make alerts